Statements (114)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Takeda_Pharmaceutical_Company
gptkb:Glaxo_Smith_Kline |
| gptkbp:acquired |
gptkb:Abb_Vie
by Abb Vie |
| gptkbp:acquisition |
gptkb:2019
acquired by Lundbeck |
| gptkbp:business_model |
biopharmaceutical development
|
| gptkbp:can_lead_to |
gptkb:Eptinezumab
|
| gptkbp:ceo |
gptkb:Mark_J._Rothera
gptkb:Dr._Randall_C._Schatzman |
| gptkbp:class |
CGRP inhibitors
|
| gptkbp:clinical_trial |
gptkb:Eptinezumab
Phase 2 Phase 3 trials randomized controlled trials innovative therapies published in journals multiple sites across the US positive results conducts clinical trials Phase 2 trials thousands of patients chronic migraine Phase 3 trials for Eptinezumab positive results in trials commercial stage multiple sites in the US Phase 1, 2, 3 |
| gptkbp:collaborations |
academic institutions
with universities partnership with pharmaceutical companies |
| gptkbp:committee |
comprised of industry experts
experts in neurology |
| gptkbp:community_engagement |
patient advocacy groups
involved in patient advocacy |
| gptkbp:competitors |
other biopharmaceutical companies
|
| gptkbp:employees |
approximately 100
|
| gptkbp:financial_performance |
quarterly earnings
reported revenue growth |
| gptkbp:focus |
development of therapies for migraine
|
| gptkbp:focus_area |
monoclonal antibodies
|
| gptkbp:founded |
gptkb:2004
|
| gptkbp:founder |
gptkb:Dr._Randall_C._Schatzman
gptkb:Randall_C._Schatzman |
| gptkbp:governed_by |
strategic partnerships
|
| gptkbp:grants |
government and private funding
|
| gptkbp:headcount |
100-200
|
| gptkbp:headquarters |
gptkb:Bothell,_Washington
|
| gptkbp:healthcare |
gptkb:2020
for Eptinezumab |
| https://www.w3.org/2000/01/rdf-schema#label |
Alder Bio Pharmaceuticals
|
| gptkbp:invention |
multiple patents for drug formulations
patents on monoclonal antibodies |
| gptkbp:investment |
institutional investors
Venture capital firms investor presentations chronic migraine secured funding from venture capital maintains communication with investors traded on NASDAQ migraine prevention market |
| gptkbp:ipo |
gptkb:2017
|
| gptkbp:language_of_instruction |
multiple drug candidates
multiple candidates multiple therapeutic candidates |
| gptkbp:leadership |
gptkb:CEO
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:market |
gptkb:2020
entered the migraine treatment market. launched Eptinezumab in 2020 on migraine treatments |
| gptkbp:market_cap |
approximately $1 billion
|
| gptkbp:marketing_strategy |
direct sales and partnerships
focus on neurology focus on migraine treatment |
| gptkbp:notable_products |
gptkb:Eptinezumab
|
| gptkbp:partnership |
gptkb:collaboration
gptkb:Pfizer collaborated with Abb Vie |
| gptkbp:partnerships |
biopharmaceutical companies
with providers strategic alliances with other companies |
| gptkbp:platform |
Ig G1 monoclonal antibodies
|
| gptkbp:population |
adults with migraines
|
| gptkbp:products |
gptkb:Eptinezumab
gptkb:monoclonal_antibody focus on innovative therapies |
| gptkbp:publishes |
peer-reviewed articles
publishes research findings |
| gptkbp:receives_funding_from |
gptkb:Company
Series A, B, C received grants for research |
| gptkbp:regulatory_compliance |
complies with FDA regulations
FDA approval for Eptinezumab FDA and EMA IND applications |
| gptkbp:research |
demonstrated in trials
focused on migraine treatment |
| gptkbp:research_areas |
neurology
neuroscience |
| gptkbp:research_focus |
gptkb:psychologist
biologics preventive treatment for migraines |
| gptkbp:safety_features |
well-tolerated
|
| gptkbp:scholarships |
resources for patients
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:subsidiary |
gptkb:Alder_Bio_Pharmaceuticals,_Inc.
|
| gptkbp:symbol |
ALDR
|
| gptkbp:team |
experienced executives in biotech
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:type |
gptkb:Company
|
| gptkbp:website |
www.alderbio.com
|